Arthritis Drug Along With an Agent Can Shut Down Gene-Mediated Lung Cancer

People with the second most common type of lung cancer, lung adenocarcinoma that is caused by gene mutations may benefit from targeted therapies.

A combination of rheumatoid arthritis drug auranofin with a targeted experimental agent can shut down one of the most common and lethal forms of lung cancer, said researchers at Mayo Clinic's Florida campus.

The combination therapy worked in a laboratory study to stop lung adenocarcinoma associated with mutation of the KRAS gene. The study will be published in the March 14, 2016 issue of Cancer Cell.

Long Telomeres Linked With an Increased Risk for Lung Adenocarcinoma
The association between that telomere length and any other cancer type or subtype was not significant. It was relevant only in the case of lung cancer.

‘The rheumatoid arthritis drug auranofin with an NOTCH3 inhibitor shows potential to treat KRAS-mediated lung adenocarcinoma tumors.’

"If our approach works in KRAS-mediated lung adenocarcinoma, it may work in other KRAS-mediated cancers, such as pancreatic and colon cancers, as well as other cancer types," says the study's senior author, Alan P. Fields, a cancer biologist and the Monica Flynn Jacoby Professor of Cancer Research in the Department of Cancer Biology at Mayo Clinic in Florida.

Based on this and other preclinical research from Dr. Fields' team, Mayo Clinic is conducting early-phase clinical trials to test the effectiveness of auranofin alone and in targeted combinations in patients with KRAS-mediated lung adenocarcinoma, ovarian cancer, and another common lung cancer called lung squamous cell carcinoma.

The current study

Identified the cancer stem cells that drive development of cancer cells in KRAS-mediated lung adenocarcinoma
Identified a major signaling pathway, or set of molecular mechanisms, that stimulates the growth of those cancer stem cells
Showed how combining auranofin and the experimental agent shut down that pathway, and may be an effective treatment approach

"Cancer stem cells are the really bad actors in many cancers," Dr. Fields says. "Cancer stem cells initiate cancer development, drive its growth and metastasis, and also develop resistance to treatments."

Researchers Identify Patterns of Mutations in Lung Adenocarcinoma
For the treatment of advanced lung adenocarcinoma, molecular driven therapeutic targets have resulted in a paradigm shift.

"Conventional chemotherapy can effectively kill non-stem cancer cells, but cancer stem cells often survive," Dr. Fields says. "Then, once therapy is stopped, these cancer stem cells can re-establish the tumor and cause a relapse."

The current research study built upon previous research from Dr. Fields' laboratory that:

Identified protein kinase C iota (PKCiota) as an oncogene - a gene that has the potential to cause cancer -- and linked it to multiple forms of cancer
Showed that auranofin inhibits PKCiota and may be useful in treating cancer
Found PKCiota activates a second oncogene, known as SOX2, to stimulate cancer stem cell growth in lung squamous cell carcinoma.

Dr. Fields says the current study surprisingly found that PKCiota regulates cancer stem cells through a different pathway in KRAS-mediated lung adenocarcinoma than in lung squamous cell carcinoma. It also activates a different oncogene, known as NOTCH3. This enabled an individualized approach.

New Potential Targets Found for Treating Squamous Cell Lung Cancers
People with the second most common type of lung cancer may one day benefit from targeted therapies that have transformed treatments for other patients, says a new paper published in Nature.

"Using this knowledge, we treated KRAS-mediated lung adenocarcinoma tumors in mice with auranofin and a NOTCH3 inhibitor," says the study's first author, Syed A. Ali, a postdoctoral researcher in Fields' lab. "We found that these two drugs work better together than either drug did alone."

"This research indicates auranofin might be useful in treating many different cancer types," Dr. Fields says. "By combining it with a second agent targeted to the specific signaling pathway, we hope to fin-tune therapy to the particular vulnerabilities of each type of tumor," Dr. Fields says.

Lung Cancer Genomes of Smokers and Never-Smokers
Lung cancer genome in people who have never smoked show greater genomic alteration than those in smokers, finds study.

"This approach may be useful in multiple forms of lung, ovarian, pancreatic, and possibly head and neck, cervical, and several other cancers," Dr. Fields says.

Source-Eurekalert